Market Overview:
The global myocardial infarction therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of myocardial infarction, rising geriatric population, and technological advancements in the field of myocardial infarction therapeutics. The global myocardial infarction therapeutics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into analgesics, antiplatelet agents, vasodilators, thrombolytics and anti-thrombotic agents (including Î’ adrenergic blockers), glycoprotein IIb/IIIa inhibitors (including monoclonal antibodies), and others. On the basis of application, the market is segmented into hospitals (inpatient settings), hospital pharmacies (outpatient settings), drug stores (retail pharmacies), online drug stores,, and others). The regional segments include North America,, Latin America,, Europe,, Asia Pacific,, Middle East & Africa,.
Product Definition:
Myocardial infarction therapeutics are treatments used to help manage and prevent heart attacks. These therapies can include medications, procedures, and lifestyle changes. The importance of myocardial infarction therapeutics lies in their ability to save lives by preventing heart attacks from occurring.
Analgesics:
Analgesics is a group of drugs that reduces the pain caused by inflammation or trauma to the skin, muscles, and other body parts. Analgesics are used for treatment of acute as well as chronic pain. The most common forms of analgesic used in medicine are NSAIDs (non-steroidal anti-inflammatory drugs) and opioids.
Antiplatelet Agents:
Antiplatelet agents are a group of drugs that reduce the tendency of blood clots to form after an injury or medical procedure. Antiplatelet drugs include anticoagulants, platelet aggregation inhibitors, and fibrinolytic agents. The most common types of anti-clotting medications used today are oral hypoglycemic agents (OHA), vitamin K antagonists (VKAs), and selective serotonin reuptake inhibitors (SSRIs).
Application Insights:
Based on application, the global myocardial infarction therapeutics market is segmented into hospitals, hospital pharmacies, and drug stores. Hospitals held the largest share in 2017 owing to factors such as a large patient base and presence of dedicated cardiac care units. Hospital pharmacies are anticipated to witness lucrative growth over the forecast period due to increasing awareness about faster treatment options among patients suffering from acute coronary syndrome (ACS).
The demand for antiplatelet agents is expected to grow at a significant rate during the forecast period owing to its ability in preventing blood clotting inside arteries thus reducing chances of heart attack or stroke. Increasing usage of these drugs along with aspirin has led towards reduced risk of death among patients suffering from ACS by more than 20%. This factor is anticipated to drive growth during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to favorable reimbursement policies, high healthcare expenditure, and increasing awareness about early diagnosis of cardiovascular diseases. Moreover, the presence of key players such as Pfizer Inc.; Merck & Co., Inc.; and Sanofi are also contributing towards market growth in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in prevalence of diabetes is also anticipated to boost product demand during the forecast period due to its well-established link with cardiac disorders like myocardial infarction (MI).
Growth Factors:
- Increasing incidence of myocardial infarction (MI) due to changing lifestyle and unhealthy eating habits.
- Growing awareness about the symptoms and risk factors of MI among people.
- Rising demand for better and more effective therapies for the treatment of MI.
- Technological advancements in the field of myocardial infarction therapeutics that are helping to improve patient outcomes.
Scope Of The Report
Report Attributes
Report Details
Report Title
Myocardial Infarction Therapeutics Market Research Report
By Type
Analgesics, Antiplatelet Agents, Vasodilators, Thrombolytics and anti-thrombotic agents, Glycoprotein IIb/IIIa inhibitors, Β adrenergic blockers, Others
By Application
Hospitals, Hospital Pharmacies, Drug Stores, Online Drug stores
By Companies
Novartis NV, Daiichi Sankyo Company Limited, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, AstraZeneca，Apotex, Sandoz, Par Pharmaceutical Companies, Mylan NV, Pfizer, Novartis NV
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
179
Number of Tables & Figures
126
Customization Available
Yes, the report can be customized as per your need.
Global Myocardial Infarction Therapeutics Market Report Segments:
The global Myocardial Infarction Therapeutics market is segmented on the basis of:
Types
Analgesics, Antiplatelet Agents, Vasodilators, Thrombolytics and anti-thrombotic agents, Glycoprotein IIb/IIIa inhibitors, Β adrenergic blockers, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Hospital Pharmacies, Drug Stores, Online Drug stores
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis NV
- Daiichi Sankyo Company Limited
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- AstraZeneca，Apotex
- Sandoz
- Par Pharmaceutical Companies
- Mylan NV
- Pfizer
- Novartis NV
Highlights of The Myocardial Infarction Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Analgesics
- Antiplatelet Agents
- Vasodilators
- Thrombolytics and anti-thrombotic agents
- Glycoprotein IIb/IIIa inhibitors
- Β adrenergic blockers
- Others
- By Application:
- Hospitals
- Hospital Pharmacies
- Drug Stores
- Online Drug stores
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Myocardial Infarction Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Myocardial infarction (MI) is a heart attack. The term "myocardial infarction" refers to the death of cardiac muscle cells in the heart. This can occur when blood flow to the heart is blocked or reduced, as can happen with atherosclerosis or other cardiovascular diseases.
Some of the key players operating in the myocardial infarction therapeutics market are Novartis NV, Daiichi Sankyo Company Limited, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, AstraZeneca，Apotex, Sandoz, Par Pharmaceutical Companies, Mylan NV, Pfizer, Novartis NV.
The myocardial infarction therapeutics market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Myocardial Infarction Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Myocardial Infarction Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Myocardial Infarction Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Myocardial Infarction Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Myocardial Infarction Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Myocardial Infarction Therapeutics Market Size and Y-o-Y Growth
4.5.2 Myocardial Infarction Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Analgesics
5.2.2 Antiplatelet Agents
5.2.3 Vasodilators
5.2.4 Thrombolytics and anti-thrombotic agents
5.2.5 Glycoprotein IIb/IIIa inhibitors
5.2.6 Β adrenergic blockers
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Hospital Pharmacies
6.2.3 Drug Stores
6.2.4 Online Drug stores
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Myocardial Infarction Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Myocardial Infarction Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Analgesics
9.6.2 Antiplatelet Agents
9.6.3 Vasodilators
9.6.4 Thrombolytics and anti-thrombotic agents
9.6.5 Glycoprotein IIb/IIIa inhibitors
9.6.6 Β adrenergic blockers
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Hospital Pharmacies
9.10.3 Drug Stores
9.10.4 Online Drug stores
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Analgesics
10.6.2 Antiplatelet Agents
10.6.3 Vasodilators
10.6.4 Thrombolytics and anti-thrombotic agents
10.6.5 Glycoprotein IIb/IIIa inhibitors
10.6.6 Β adrenergic blockers
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Hospital Pharmacies
10.10.3 Drug Stores
10.10.4 Online Drug stores
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Analgesics
11.6.2 Antiplatelet Agents
11.6.3 Vasodilators
11.6.4 Thrombolytics and anti-thrombotic agents
11.6.5 Glycoprotein IIb/IIIa inhibitors
11.6.6 Β adrenergic blockers
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Hospital Pharmacies
11.10.3 Drug Stores
11.10.4 Online Drug stores
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Analgesics
12.6.2 Antiplatelet Agents
12.6.3 Vasodilators
12.6.4 Thrombolytics and anti-thrombotic agents
12.6.5 Glycoprotein IIb/IIIa inhibitors
12.6.6 Β adrenergic blockers
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Hospital Pharmacies
12.10.3 Drug Stores
12.10.4 Online Drug stores
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Analgesics
13.6.2 Antiplatelet Agents
13.6.3 Vasodilators
13.6.4 Thrombolytics and anti-thrombotic agents
13.6.5 Glycoprotein IIb/IIIa inhibitors
13.6.6 Β adrenergic blockers
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Hospital Pharmacies
13.10.3 Drug Stores
13.10.4 Online Drug stores
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Myocardial Infarction Therapeutics Market: Competitive Dashboard
14.2 Global Myocardial Infarction Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis NV
14.3.2 Daiichi Sankyo Company Limited
14.3.3 Bristol-Myers Squibb Company
14.3.4 Boehringer Ingelheim GmbH
14.3.5 AstraZeneca，Apotex
14.3.6 Sandoz
14.3.7 Par Pharmaceutical Companies
14.3.8 Mylan NV
14.3.9 Pfizer
14.3.10 Novartis NV
